How has been the historical performance of Alembic Pharma?

Answer:The historical performance of Alembic Pharma shows a consistent growth trend in net sales and operating income over the years, culminating in a net sales figure of 6,672.08 Cr for the year ending March 2025. This represents an increase from 6,228.63 Cr in March 2024 and 5,652.62 Cr in March 2023. The total expenditure, excluding depreciation, also rose to 5,663.85 Cr in March 2025, up from 5,295.27 Cr the previous year. Operating profit, measured as PBDIT, reached 1,050.78 Cr in March 2025, reflecting a steady increase from 961.67 Cr in March 2024 and 711.11 Cr in March 2023. However, profit after tax showed some fluctuation, decreasing to 581.14 Cr in March 2025 from 616.80 Cr in March 2024, although it was higher than 372.91 Cr in March 2023. The company's total assets increased to 7,606.90 Cr in March 2025, compared to 6,275.94 Cr in March 2024, while total liabilities also rose to 7,606.90 Cr from 6,275.94 Cr. The cash flow from operating activities saw a decline to 87.00 Cr in March 2025 from 803.00 Cr in March 2024, and the net cash outflow was recorded at -36.00 Cr for the same period.

Breakdown:
Alembic Pharma has demonstrated a robust growth trajectory in its financial performance over the years. The company's net sales have consistently increased, reaching 6,672.08 Cr in March 2025, up from 6,228.63 Cr in the prior year. This growth in revenue has been accompanied by a rise in total operating income, which also hit 6,672.08 Cr in March 2025. Despite the increase in total expenditure to 5,663.85 Cr, the operating profit (PBDIT) improved to 1,050.78 Cr, indicating effective cost management. However, profit after tax experienced a slight decline to 581.14 Cr in March 2025, down from 616.80 Cr in March 2024, reflecting some volatility in profitability. The total assets of the company increased significantly to 7,606.90 Cr, alongside a rise in total liabilities, which suggests a growing balance sheet. The cash flow from operating activities decreased notably to 87.00 Cr, highlighting potential challenges in cash generation despite the overall growth in sales and profits.